Financial News
Articles published by Neurogene Inc.
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
November 18, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
November 18, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Announces Oversubscribed $200 Million Private Placement
November 04, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
August 09, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
August 07, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene to Participate in BMO Genetic Medicines Summit
July 02, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Announces Addition to Russell 3000® Index
July 01, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene to Participate in Upcoming Conferences
June 05, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
June 03, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
March 18, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene to Participate in Upcoming Investor Conferences
February 29, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Neurogene Announces Business Update and 2024 Outlook
January 05, 2024
From Neurogene Inc.
Via Business Wire
Tickers
NGNE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.